Abstract
Purpose
MAG-camptothecin (MAG-CPT) is the lead compound of a novel drug delivery system in which an active cytotoxic moiety, camptothecin (CPT), is covalently linked to a soluble polymeric carrier (MAG) to form an inactive prodrug. The mechanism of action of CPT remains unaltered, but the delivery system is thought to allow the carrier-bound drug to accumulate in tumor tissues and release the active CPT locally. This proof-of-concept clinical study was designed to determine whether MAG-CPT was preferentially delivered to or retained in tumor tissue compared to adjacent normal tissue or plasma, and to estimate the degree of intratissue release of CPT.
Methods
This was an open, non-randomized study in ten adult patients scheduled for elective surgery for colorectal cancer. Patients received a single dose of 60 mg/m2 (CPT equivalent) of MAG-CPT 24 h, 3 days or 7 days prior to surgery. Plasma, tumor, and adjacent normal tissue samples were collected simultaneously at the time of surgery and analyzed for MAG-bound and released CPT concentrations.
Results
MAG-bound and free CPT concentrations in plasma, tumor, and normal tissue achieved equilibrium by 24 h after dosing, declining in parallel up to 7 days after dosing. MAG-bound CPT was delivered to similar levels to tumor and normal tissue. At 24 h after dosing, the mean±SD MAG-bound CPT concentrations were 861±216 ng/g in tumor and 751±215 ng/g in adjacent normal tissue, and free CPT concentrations were lower in tumor than in normal tissue (12.2±4.7 ng/g and 21.9±6.7 ng/g, respectively). At 24 h after dosing, mean±SD ratios of MAG-bound and free CPT in tumor and plasma were 0.13±0.03 and 0.22±0.09, respectively, and the ratios did not change for up to 7 days after dosing, indicating a lack of preferential retention of MAG-bound CPT or release of free CPT in tumor. These results are in marked contrast to previous data from animal tumor xenograft studies, where MAG-CPT levels were higher in tissue than in plasma at 3 and 7 days after a single i.v. dose.
Conclusions
Delivery of CPT to the target tumor tissue is achievable by means of the MAG-CPT polymer-bound delivery system, with the equilibrium between plasma and tumor tissue concentrations of released CPT being established within 24 h after dosing. However, preferential retention of MAG-bound or released CPT in the tumor relative to normal tissue or plasma was not detected during the 7 days after dosing. The methods employed in our study could be of use in making "go/no-go" decisions on further development of anticancer drugs.
Similar content being viewed by others
References
Batist G, Ramakrishnan G, Rao CS, Chandrasekharan A, Gutheil J, Guthrie T, Shah P, Khojasteh A, Nair MK, Hoelzer K, Tkaczuk K, Park YC, Lee LW (2001) Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer. J Clin Oncol 19:1444
Baxter LT, Zhu H, Mackensen DG, Butler WF, Jain RK (1995) Biodistribution of monoclonal antibodies: scale-up from mouse to human using a physiologically based pharmacokinetic model. Cancer Res 55:4611
Bergh J (2002) Is pharmacokinetically guided chemotherapy dosage a better way forward? Ann Oncol 13:343
Brem H, Piantudosi S, Burger PC, Walker M, Selker R, Vick NA, Black K, Sisti M, Brem S, Mohr G, Muller P, Morawetz R, Schold SC (1995) Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. Lancet 345:1008
Caiolfa VR, Zamai M, Fiorino A, Frigerio E, Pellizzoni C, d'Argy R, Ghiglieri A, Castelli MG, Farao M, Pesenti E, Gigli M, Angelucci F, Suarato A (2000) Polymer-bound camptothecin: initial biodistribution and antitumour activity studies. J Controlled Release 65:105
Creaven PJ, Allen LM, Muggia FM (1972) Plasma camptothecin (NSC-100880) levels during a 5-day course of treatment: relation to dose and toxicity. Cancer Chemother Rep 56:573
de Bono JS, Bissett D, Twelves C, Cassidy M (2000) Phase I pharmacokinetic (PK) study of MAG-CPT (PNU-166148), a polymeric derivative of camptothecin (CPT) (abstract 771). Proc ASCO 19:198a
Fox E, Curt GA, Balis FM (2002) Clinical trial design for target-based therapy. Oncologist 7:401
Fraier D, Frigerio E, Brianceschi G, Casati M, Benecchi A, James C (2000) Determination of MAG-camptothecin, a new polymer-bound camptothecin derivative, and free camptothecin in dog plasma by HPLC with fluorimetric detection. J Pharm Biomed Anal 22:505
Gerweck LE (1998) Tumor pH: implications for treatment and novel drug design. Semin Radiat Oncol 8:176
Gottlieb JA, Guarino AM, Call JB, Oliverio VT, Block JB (1970) Preliminary pharmacologic and clinical evaluation of camptothecin sodium (NSC-100880). Cancer Chemother Rep 54:461
Harrington KJ, Lewanski CR, Stewart JSW (2000) Liposomes as vehicles for targeted therapy of cancer. Part 2: clinical development. Clin Oncol 12:16
Helmlinger G, Sckell A, Dellian M, Forbes NS, Jain RK (2002) Acid production in glycolysis-impaired tumors provides new insights into tumor metabolism. Clin Cancer Res 8:1284
Jain RK (1994) Barriers to drug delivery in solid tumors. Sci Am 271:58
Jain RK (1996) Delivery of molecular medicine to solid tumors. Science 271:1079
Jain RK (2001) Delivery of molecular and cellular medicine to solid tumors. Adv Drug Deliv Rev 46:149
Kehrer DFS, Soepenberg O, Loos WJ, Verweij J, Sparreboom A (2001) Modulation of camptothecin analogs in the treatment of cancer: a review. Anticancer Drugs 12:89
Koopmans PP (2002) Clinical endpoints in trials of drugs for cancer: time for a rethink? BMJ 324:1389
Kopeček J, Kopečková P, Minko T, Lu Z-R, Peterson CM (2001) Water soluble polymers in tumor targeted delivery. J Controlled Release 74:147
Korn EL, Arbuck SG, Pluda JM, Simon R, Kaplan RS, Christian MC (2001) Clinical trial designs for cytostatic agents: are new approaches needed? J Clin Oncol 19:265
Luo Y, Prestwich GD (2002) Cancer-targeted polymeric drugs. Curr Cancer Drug Targets 2:209
Maeda H, Matsumura Y (1989) Tumoritropic and lymphotropic principles of macromolecular drugs. CRC Crit Ther Drug Carrier System 6:193
Mendichi R, Rizzo V, Gigli M, Schieroni AG (2002) Fractionation and characterization of a conjugate between a polymeric drug-carrier and the antitumor drug camptothecin. Bioconjug Chem 13:1253–1258
Moertel CG, Schutt AJ, Reitemeier RJ, Hahn RG (1972) Phase II study of camptothecin (NSC-100880) in the treatment of advanced gastrointestinal cancer. Cancer Chemother Rep 56:95
Muggia FM, Creaven PJ, Hansen H, Cohen MH, Selawry OS (1972) Phase I clinical trial of weekly and daily treatment with camptothecin (NSC-100880): correlation with preclinical studies. Cancer Chemother Rep 56:515
Napier MP, Sharma SK, Springer CJ, Bagshawe KD, Green AJ, Martin J, Stribbling SM, Cushen N, O'Malley D, Begent RH (2000) Antibody-directed enzyme prodrug therapy: efficacy and mechanism of action in colorectal carcinoma. Clin Cancer Res 6:765
Rowinsky EK (2000) The pursuit of optimal outcomes in cancer therapy in a new age of rationally designed target-based anticancer agents. Drugs 60 [Suppl 1]:1
Saijo N, Tamura T, Nishio K (2000) Problems in the development of target-based drugs. Cancer Chemother Pharmacol 46:S43
Schoemaker NE, Frigerio E, Fraier D, Shellens JHM, Rosing H, Jansen S, Beijnen JH (2001) High-performance liquid chromatographic analysis for the determination of a novel polymer-bound camptothecin derivative (MAG-camptothecin) and free camptothecin in human plasma. J Chromatogr 763:173
Skinner SA, Tutton PJ, O'Brien PE (1990) Microvascular architecture of experimental colon tumors in the rat. Cancer Res 50:2411
Takakura Y, Hashida M (1995) Macromolecular drug carrier systems in cancer chemotherapy: macromolecular prodrugs. Crit Rev Oncol Hematol 18:207
Tan AR, Swain SM (2001) Novel agents: clinical trial design. Semin Oncol 28:148
Ulbrich K, Strohalm J, Kopecek J (1981) Polymers containing enzymatically degradable bonds. 3. Poly[N-(2-hydroxypropyl)methacrylamide]chains connected by oligopeptide sequences cleavable by trypsin. Makromol Chem 182:1917
Zamai M, vandeVen M, Farao M, Gratton E, Ghiglieri A, Castelli MG, Fontana E, d'Argy R, Fiorino A, Pesenti E, Suarato A, Caiolfa VR (2003) Camptothecin poly[N-(2-hydroxypropyl) methacrylamide] copolymers in antitopoisomerase-I tumor therapy: intratumor release and antitumor efficacy. Mol Cancer Ther 2:29
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Sarapa, N., Britto, M.R., Speed, W. et al. Assessment of normal and tumor tissue uptake of MAG-CPT, a polymer-bound prodrug of camptothecin, in patients undergoing elective surgery for colorectal carcinoma. Cancer Chemother Pharmacol 52, 424–430 (2003). https://doi.org/10.1007/s00280-003-0685-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00280-003-0685-x